title: Emerging therapies for thyroid carcinoma.
abstract: Thyroid carcinoma is the most commonly diagnosed endocrine malignancy. Its incidence is currently rising worldwide. The discovery of genetic mutations associated with the development of thyroid cancer, such as BRAF and RET, has lead to the development of new drugs which target the pathways which they influence. Despite recent advances, the prognosis of anaplastic thyroid carcinoma is still unfavourable. In this review we look at emerging novel therapies for the treatment of well-differentiated and medullary thyroid carcinoma, and advances and future directions in the management of anaplastic thyroid carcinoma.
authors.affiliation: Department of Surgery, RCSI Smurfitt Building, Beaumont Hospital, Dublin 9, Ireland. siunw@yahoo.co.uk
authors.forename: S
authors.initials: S
authors.lastname: Walsh
authors.forename: R
authors.initials: R
authors.lastname: Prichard
authors.forename: A D K
authors.initials: AD
authors.lastname: Hill
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D018278:Carcinoma, Neuroendocrine; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction; D065646:Thyroid Carcinoma, Anaplastic; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors